Gathering the record
Relay is organizing the evidence and source boundaries.
Monoamine reuptake-inhibitor small molecule
Tesofensine is an oral small molecule that inhibits reuptake of dopamine, norepinephrine, and serotonin and has been studied for obesity.
60-Second Overview
Start with what it is, why it matters, what research has shown, and what remains unknown. The science follows after the orientation.
Start here. These four answers explain why the compound matters before the page introduces the deeper science.
Tesofensine is an investigational oral small molecule that changes the recycling of three brain messengers involved in appetite, attention, mood, and cardiovascular activity.
Researchers studied whether influencing dopamine, norepinephrine, and serotonin together could reduce appetite and body weight. That same broad activity makes heart rate, sleep, mood, and misuse-related effects important to the evidence story.
A 24-week randomized Phase 2 obesity trial reported greater average weight reduction with tesofensine than placebo across the studied groups. Other controlled work examined acute misuse potential and a combination treatment in a rare hypothalamic-obesity population.
Long-term cardiovascular and neuropsychiatric safety, durability, uncommon harms, performance in diverse populations, and the benefit-risk balance beyond Phase 2 remain unresolved. Tesofensine is not FDA approved.
The research depth, routes, studies, and primary sources below explain how Relay knows—and where the evidence stops.
Research context
Published research has investigated this compound using the following study designs.
These records explain what researchers did. They are not instructions, recommendations, or a transferable protocol.
A published Phase 2 trial investigated oral tesofensine in adults with obesity, focusing on weight, body composition, quality of life, and tolerability.
Reported study administration—not a recommendation.
Research at a glance
Evidence depth, confidence, and route context explain how Relay knows—not what anyone should do.
Controlled human obesity evidence with cardiovascular, neuropsychiatric, and long-term outcome questions.
Research depth describes how large and mature the overall record is. It does not tell you whether the results were positive.
Whether longer-term benefits outweigh cardiovascular, neuropsychiatric, sleep, and misuse-related risks in larger diverse populations.
Confidence describes how reliable and consistent the conclusions are. It can be high for one outcome and low for another.
The strongest evidence type shows what the best-supported conclusions are actually based on.
Human findings are more directly relevant than animal or laboratory results, but they still apply only to the populations and outcomes studied.
Route-specific record
These are exposures used in cited research for a specific route and population—not an instruction for an individual.
Half-life describes how long it takes the measured amount in the body to fall by half. It is not a dosing recommendation.
Evidence can change by administration method. Findings from one route should not automatically be applied to another.
Evidence boundary: The study lasted 24 weeks and cannot resolve long-term cardiovascular, sleep, mood, or misuse-related outcomes. Later combination research cannot be assigned to tesofensine alone or converted into an approved regimen. Amounts shown describe cited research exposure—not a dosage recommendation.
Detailed evidence
Start with the strongest supported conclusion and its main uncertainty. Claim-level records below show how the evidence changes by question, population, route, formulation, and study design.
A 24-week randomized Phase 2 obesity trial reported dose-related weight loss versus placebo.
This is the strongest supported conclusion in the current human evidence—not a summary of every claim made about the compound.
Whether longer-term benefits outweigh cardiovascular, neuropsychiatric, sleep, and misuse-related risks in larger diverse populations.
Keeping the main uncertainty visible prevents an early or promising finding from looking more settled than it is.
Questions people bring to the evidence
Research questions—not promises of benefit.
This is the strongest human-evidence boundary in the current record.
Mechanistic findings explain biological plausibility; they do not establish a human outcome.
Relay keeps this uncertainty visible rather than converting it into a prediction.
The safety snapshot reflects the studied record and its limitations.
Regulatory and identity status determine how the evidence should be interpreted.
Mechanisms
A Phase 2 obesity trial reported substantial weight loss over 24 weeks, alongside pulse and other tolerability findings. Later combination research does not make tesofensine monotherapy approved or broadly established.
A plausible mechanism can explain why a study was attempted. It does not prove that the compound improves a human outcome.
Studies
Study arms are reported for transparency. They describe what researchers did in a defined record and do not transfer across identities, routes, formulations, or populations.
A later trial phase can ask a more mature question, but it does not guarantee a positive result, regulatory approval, or relevance outside the studied population.
Randomized double-blind placebo-controlled trial
Adults with obesity
In a 24-week Phase 2 trial, tesofensine produced dose-related weight loss greater than placebo.
Study administration: Multiple oral tesofensine doses versus placebo
Limitations: Phase 2 size and duration; pulse and tolerability findings require longer outcome research.
Randomized crossover human abuse-potential study
Recreational stimulant users
Endpoints were not fully described in the current record.
A controlled study evaluated subjective and pharmacologic effects relevant to misuse potential.
Study administration: Not stated in the current record.
Limitations: Acute specialized design does not establish longer-term misuse risk.
Randomized placebo-controlled trial
Adults with hypothalamic obesity
Endpoints were not fully described in the current record.
Combination research explored tesofensine plus metoprolol in a rare hypothalamic-obesity population.
Study administration: Not stated in the current record.
Limitations: Combination and rare-disease evidence cannot be attributed to tesofensine alone.
Safety snapshot
Trials report dry mouth, nausea, constipation, sleep disturbance, and increased heart rate in some groups; longer-term cardiovascular and neuropsychiatric safety remains central.
Controlled human evidenceReported events depend on population, formulation, route, exposure, comparator, and study size.
Open sourceThe current record does not support a reliable common-versus-uncommon frequency split.
Evidence boundaryUnder-detected or under-reported events must not be described as rare.
No source-qualified compound-specific warning or contraindication is encoded in the current record.
Evidence boundaryInvestigational; no FDA-approved tesofensine product. Whether longer-term benefits outweigh cardiovascular, neuropsychiatric, sleep, and misuse-related risks in larger diverse populations.
The current record does not identify a reliable compound-specific pattern of events that caused study discontinuation.
Evidence boundaryThis is an evidence gap, not proof that discontinuations did not occur.
No compound-specific patient-facing urgent-action threshold is established in the current Relay record.
Evidence boundaryRelay does not infer emergency guidance from study discontinuations, mechanism, or incomplete adverse-event reporting.
Community
Built by the community
Every structured report adds useful context about research setup, outcomes, and unwanted effects as the community dataset grows.
Publicly anonymous by default. Your account keeps reports editable and helps reduce duplicate submissions.Sources
PMID 18950853
PMID 20520602
PMID 35294397